Efficacy of GBT vs SRP+US, in the Treatment of Severe Generalized Periodontitis. (ERISRP)

Efficacy of Combined Air-abrasive+Ultrasonic (Guided Biofilm Therapy GBT) vs. Standard Root Debridement (Scaling and Root Planing+ Ultrasonic SRP+US) in the Treatment of Severe Generalized Periodontitis: A Randomized Clinical Trial

The first step in the management of periodontal disease involves the non-surgical removal of the soft and hard bacterial deposits at all supra- and sub-gingival sites, especially into deep pockets, which can be carried on with different instruments.

Unfortunately it seems that, after the initial therapy, many patients still present with active pockets (residual pockets) requiring further treatment and posing a risk of disease progression. This might be due to limitations of the instruments applied and patient-related factors. Air-polishing with low-abrasiveness powders seems to be very effective in the removal of supra- and sub-gingival biofilm and could provide additional benefits during the treatment of pockets.

The aim of this randomized, controlled, split-mouth study was to compare the efficacy of full-mouth air-polishing followed by ultrasonic debridement (GBT) versus traditional Scaling and Root Planing (SRP), in terms of pocket closure in patients with stage III-IV periodontitis.

To test this hypothesis, the mouth of each patients, upon initial evaluation, were divided in 2 parts:

  1. The control group undergoing a standard procedure: ultrasonic debridement with an ultrasonic scaler for remove supra and sub gingival calculus, manual debridement with curettes at deep pathological pockets (PPD > 4mm) and rubber cup with polishing to remove supra gingival biofilm and plaque.
  2. The study group undergoing the innovative air polishing procedure: airflow with erythritol powder to remove supra and sub gingival biofilm and plaque, perioflow at deep pathological pockets (PPD > 4mm) and ultrasonic debridement with an ultrasonic scaler for remove supra and sub gingival calculus.

The prevalence of residual pockets will be evaluated at 6 weeks and 3 months after the initial therapy and compared between the two groups.

Study Overview

Detailed Description

TRIAL DESIGN:

A prospective, single-masked, randomized, split-mouth, longitudinal clinical trial.

OUTCOME:

  1. The primary outcome was the number of experimental sites (PPD >4mm and <10mm) becoming closed pockets (PPD ≤ 4mm) at 6 weeks (T1) and 3 months (T2) after initial therapy.
  2. Secondary outcomes were the variations in PPD, REC (Clinical Gingival Recession), CAL (Clinical Attachment Level), BOP (Bleeding On Probing) and PI (Plaque Index) at the experimental sites and treatment time.

A 10% difference in the primary outcome between the two protocols was set as the threshold to define inferiority/non-inferiority of the Test treatment.

STUDY POPULATION:

thirty-two (32) adults, aged 18-75 years, will be entered into study (randomized).

Randomized subjects who deviate from the protocol (major protocol deviation) and, for this reason, are excluded from the analysis, will be replaced to guarantee that the sample required for the analysis (32) is reached.

INCLUSION CRITERIA:

  • Signed Informed Consent Form.
  • Male and female subjects, aged 18-75 years, inclusive.
  • Good general health (free of systemic diseases such as diabetes, HIV infection or genetic disorder, ongoing malignant disease of any type that could influence the outcome of the treatment and might interfere with the evaluation of the study objectives).
  • Diagnosis of Stage III-IV periodontitis;17
  • At least 6 sites per quadrant with Pocket Probing Depth (PPD) ≥ 3mm;
  • At least 5 teeth per quadrant;
  • Availability for the 3-month duration of the study for an assigned subject.

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Lombardia
      • Brescia, Lombardia, Italy, 25123
        • Magda Mensi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Signed Informed Consent Form.
  • Male and female subjects, aged 18-75 years, with diagnosis of severe generalized periodontitis.
  • Good general health (free of systemic diseases such as diabetes, HIV infection or genetic disorder, ongoing malignant disease of any type that could influence the outcome of the treatment and might interfere with the evaluation of the study objectives).
  • Diagnosis of Stage III-IV periodontitis;
  • At least 6 sites per quadrant with Pocket Probing Depth (PPD) ≥ 3mm;
  • At least 5 teeth per quadrant;
  • Availability for the 3-month duration of the study for an assigned subject.

Exclusion Criteria:

  • Severe Smoking more than 10 cigarettes per day
  • Pregnancy or nursing.
  • Radiotherapy or Chemotherapy.
  • BPCO (chronic obstructive pulmonary disease), asma.
  • Systemic long-term corticosteroid treatment.
  • Antibiotic treatment in the period of 3 months before the start of the study.
  • Non surgical therapy in the period of 3 months before the start of the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Guided Biofilm Therapy
Airflow with erythritol powder to remove supra and sub gingival biofilm and plaque, perioflow with erythritol powder at deep pathological pockets (PPD > 4mm) and ultrasonic debridement with an ultrasonic scaler for remove supra and sub gingival calculus.
Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
Active Comparator: Scaling and Root Planning - Ultrasonic Debridement
Ultrasonic debridement with an ultrasonic scaler for remove supra and sub gingival calculus, manual debridement with curettes at deep pathological pockets (PPD > 4mm) and rubber cup with polishing to remove supra gingival biofilm and plaque.
traditional Scaling and Root Planing with curettes and ultrasonic scaler

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The number of experimental sites (PPD > 4mm and <10mm) becoming closed pockets (PPD ≤ 4mm).
Time Frame: 3 months after initial therapy.
A 10% difference in the primary outcome between the two protocols was set as the threshold to define inferiority/non-inferiority of the Test treatment.
3 months after initial therapy.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in PPD (periodontal depth)
Time Frame: 3 months after initial therapy.
Change in mean PD value for each patient measured (from the gingival margin to the bottom of the pocket). Baseline values will be compared to the values recorded in the follow-up visits.
3 months after initial therapy.
Change in REC (Clinical Gingival Recession)
Time Frame: 3 months after initial therapy.
Change in mean of REC value for each patient should be calculated. Baseline values will be compared to the values recorded in the follow-up visits.
3 months after initial therapy.
Change in CAL (Clinical Attachment Level)
Time Frame: 3 months after initial therapy.
Change in mean of CAL value for each patient should be calculated. Baseline values will be compared to the values recorded in the follow-up visits.
3 months after initial therapy.
Change in BOP (Bleeding on Probing)
Time Frame: 3 months after initial therapy.
Change in percentage of sites positive to bleeding on probing. Baseline values will be compared to the values recorded in the follow-up visits.
3 months after initial therapy.
Change in PI (Plaque Index)
Time Frame: 3 months after initial therapy.
Change in percentage of site with plaque. Baseline values will be compared to the values recorded in the follow-up visits.
3 months after initial therapy.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Magda Mensi, ASST Spedali Civili di Brescia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 22, 2016

Primary Completion (Actual)

September 4, 2018

Study Completion (Actual)

April 4, 2020

Study Registration Dates

First Submitted

October 21, 2021

First Submitted That Met QC Criteria

November 3, 2021

First Posted (Actual)

November 8, 2021

Study Record Updates

Last Update Posted (Actual)

November 8, 2021

Last Update Submitted That Met QC Criteria

November 3, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Periodontitis

Clinical Trials on Airflow, Perioflow and Erythritol powder and ultrasonic debridement

3
Subscribe